Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670358 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 138
- Enrollment target
NCT00670358: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00670358 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 138 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00670358, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 138 participants
- Enrollment target
Study Summary
RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with rituximab and combination chemotherapy may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of lenalidomide when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with newly diagnosed stage II, stage III, or stage IV diffuse large cell or follicular B-cell lymphoma.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- DRUG lenalidomide
- DRUG doxorubicin hydrochloride
- BIOLOGICAL pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2008-08-25 |
| Est. Completion | 2024-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00670358
The ClinicalTrials.gov registry entry for NCT00670358 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00670358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00670358 about?
NCT00670358 is a clinical study titled "Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma". RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or...
What is the current status of trial NCT00670358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2008-08-25. Estimated completion is 2024-10-04.
What interventions are being tested in trial NCT00670358?
The interventions under investigation include: cyclophosphamide (DRUG), rituximab (BIOLOGICAL), lenalidomide (DRUG), doxorubicin hydrochloride (DRUG), pegfilgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00670358?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.